The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis

Ovarian cancer is the most lethal gynecologic malignancy, and metastasis is the major cause of death in patients with ovarian cancer, which is regulated by the coordinated interplay of genetic and epigenetic mechanisms. Histone deacetylases (HDACs) are enzymes that can catalyze the deacetylation of histone and some non-histone proteins and that are involved in the regulation of a variety of biological processes via the regulation of gene transcription and the functions of non-histone proteins such as transcription factors and enzymes. Aberrant expressions of HDACs are common in ovarian cancer. Many studies have found that HDACs are involved in regulating a variety of events associated with ovarian cancer metastasis, including cell migration, invasion, and the epithelial–mesenchymal transformation. Herein, we provide a brief overview of ovarian cancer metastasis and the dysregulated expression of HDACs in ovarian cancer. In addition, we discuss the roles of HDACs in the regulation of ovarian cancer metastasis. Finally, we discuss the development of compounds that target HDACs and highlight their importance in the future of ovarian cancer therapy.

[1]  Jiong Cai,et al.  EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A , 2023, Current Medical Science.

[2]  Xuelin Li,et al.  Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer. , 2023, Gynecologic oncology.

[3]  Yuxin Chen,et al.  Tumor microenvironment in ovarian cancer peritoneal metastasis , 2023, Cancer Cell International.

[4]  Jieyu Wang,et al.  The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer , 2023, Journal of Translational Medicine.

[5]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[6]  Michal Kielbik,et al.  E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer , 2022, International journal of molecular sciences.

[7]  M. Zhang,et al.  METTL3-mediated N6-methyladenosine modification and HDAC5/YY1 promote IFFO1 downregulation in tumor development and chemo-resistance. , 2022, Cancer letters.

[8]  Sendurai A Mani,et al.  Mechanisms of cancer metastasis. , 2022, Seminars in cancer biology.

[9]  D. Barathi,et al.  Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer , 2022, Medical Oncology.

[10]  Jelena Melesina,et al.  Current trends in development of HDAC-based chemotherapeutics. , 2022, Life sciences.

[11]  A. Munshi,et al.  Differential molecular mechanistic behavior of HDACs in cancer progression , 2022, Medical Oncology.

[12]  D. Kumar,et al.  Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer , 2022, Frontiers in Chemistry.

[13]  A. Bode,et al.  The emerging roles of HDACs and their therapeutic implications in cancer. , 2022, European journal of pharmacology.

[14]  Go-woon Kim,et al.  HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells , 2022, International journal of molecular sciences.

[15]  U. Ray,et al.  SIRT6 promotes mitochondrial fission and subsequent cellular invasion in ovarian cancer , 2022, FEBS open bio.

[16]  S. Lheureux,et al.  Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. , 2022, Seminars in cancer biology.

[17]  R. Gafà,et al.  The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma , 2022, Frontiers in Oncology.

[18]  Y. Ye,et al.  Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer , 2022, Frontiers in Cell and Developmental Biology.

[19]  Jing Su,et al.  HDAC9 Contributes to Serous Ovarian Cancer Progression through Regulating Epithelial–Mesenchymal Transition , 2022, Biomedicines.

[20]  Wen-quan Wang,et al.  Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[21]  Tingting Wu,et al.  microRNA-671-5p reduces tumorigenicity of ovarian cancer via suppressing HDAC5 and HIF-1α expression. , 2022, Chemico-biological interactions.

[22]  Huiyu Zhuang,et al.  FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma , 2021, Journal of Translational Medicine.

[23]  O. Aras,et al.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. , 2021, European journal of medicinal chemistry.

[24]  Gang Yin,et al.  Characterization of Histone Deacetylase Mechanisms in Cancer Development , 2021, Frontiers in Oncology.

[25]  P. Kunda,et al.  Linoleic and oleic acids enhance cell migration by altering the dynamics of microtubules and the remodeling of the actin cytoskeleton at the leading edge , 2021, Scientific Reports.

[26]  G. Nagaraju,et al.  Epigenetics in hepatocellular carcinoma. , 2021, Seminars in cancer biology.

[27]  L. A. Alves Avelar,et al.  A short overview of resistance to approved histone deacetylase inhibitors. , 2021, Future medicinal chemistry.

[28]  C. Maher,et al.  Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.

[29]  Fabin Dang,et al.  Targeting the acetylation signaling pathway in cancer therapy. , 2021, Seminars in cancer biology.

[30]  P. Korkolopoulou,et al.  Targeting post-translational histone modifying enzymes in glioblastoma. , 2020, Pharmacology & therapeutics.

[31]  J. Dimmock,et al.  Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy , 2020, Cancers.

[32]  Arash Salmaninejad,et al.  Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles , 2020, Cellular Oncology.

[33]  D. Matei,et al.  Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes , 2020, Cancer Research.

[34]  F. Giorgi,et al.  Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability , 2020, Genes.

[35]  Hongtian Zhu,et al.  Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group , 2020, Frontiers in Chemistry.

[36]  R. L. Hollis,et al.  Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data , 2020, BJOG : an international journal of obstetrics and gynaecology.

[37]  R. Bast,et al.  SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters , 2020, International journal of cancer.

[38]  B. Conley,et al.  Histone Deacetylation , 2020, Drugs in R&D.

[39]  Yingjie Zhang,et al.  Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present) , 2020, Expert opinion on therapeutic patents.

[40]  Kriti Kashyap,et al.  Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study , 2020, Journal of biomolecular structure & dynamics.

[41]  Zhenyu Zhang,et al.  HDAC3 positively regulates HE4 expression to promote ovarian carcinoma progression. , 2019, Archives of biochemistry and biophysics.

[42]  Yunlan Tang,et al.  SIRT1 and p300/CBP regulate the reversible acetylation of serine-threonine kinase NDR2. , 2019, Biochemical and biophysical research communications.

[43]  R. Fodde,et al.  Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance , 2019, Journal of clinical medicine.

[44]  Qian Zhang,et al.  Design, synthesis, and biological evaluation of target water‐soluble hydroxamic acid‐based HDACi derivatives as prodrugs , 2019, Chemical biology & drug design.

[45]  Xiaoqing Zhu,et al.  Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis , 2019, OncoTargets and therapy.

[46]  Xianghui Yu,et al.  G9a and histone deacetylases are crucial for Snail2‐mediated E‐cadherin repression and metastasis in hepatocellular carcinoma , 2019, Cancer science.

[47]  S. Wuchty,et al.  Promoter conservation in HDACs points to functional implications , 2019, BMC Genomics.

[48]  Jinsong Liu,et al.  Cytoplasmic SIRT1 inhibits cell migration and invasion by impeding epithelial–mesenchymal transition in ovarian carcinoma , 2019, Molecular and Cellular Biochemistry.

[49]  T. Tan,et al.  SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition , 2019, Scientific Reports.

[50]  G. Berx,et al.  The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance , 2019, Cancers.

[51]  A. Oza,et al.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine , 2019, CA: a cancer journal for clinicians.

[52]  Jhin Jieh Lim,et al.  Epigenetics of hepatocellular carcinoma , 2019, Clinical and Translational Medicine.

[53]  Ying Yan,et al.  PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors , 2019, eLife.

[54]  R. S. Conlan,et al.  HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[55]  E. Rudolf,et al.  The effect of sodium butyrate and cisplatin on expression of EMT markers , 2019, PloS one.

[56]  M. Barbolina,et al.  Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma , 2018, Cancers.

[57]  Chunaram Choudhary,et al.  Functions and mechanisms of non-histone protein acetylation , 2018, Nature Reviews Molecular Cell Biology.

[58]  P. Mandal,et al.  HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. , 2018, European journal of medicinal chemistry.

[59]  Wei Zhang,et al.  Histone deacetylase 6 in cancer , 2018, Journal of Hematology & Oncology.

[60]  Liam J. Drew.  The unexpected role of histones in childhood brain cancer , 2018, Nature.

[61]  Yuquan Wei,et al.  Epigenetics in ovarian cancer: premise, properties, and perspectives , 2018, Molecular Cancer.

[62]  Ewgenij Proschak,et al.  Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. , 2018, Journal of medicinal chemistry.

[63]  W. Jiang,et al.  Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer. , 2018, European review for medical and pharmacological sciences.

[64]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[65]  Xinjian Zhang,et al.  SIRT1 deacetylates KLF4 to activate Claudin‐5 transcription in ovarian cancer cells , 2018, Journal of cellular biochemistry.

[66]  Jian Zhang,et al.  Zinc binding groups for histone deacetylase inhibitors , 2018, Journal of enzyme inhibition and medicinal chemistry.

[67]  K. Lisowska,et al.  Advances in ovarian cancer therapy , 2017, Cancer Chemotherapy and Pharmacology.

[68]  Phillip A. Richmond,et al.  Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers , 2017, Nucleic acids research.

[69]  J. Castellví,et al.  E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness , 2017, PloS one.

[70]  E. Chan,et al.  In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases. , 2017, Biochemistry.

[71]  E. Goode,et al.  Epigenetics in ovarian cancer. , 2017, Seminars in cancer biology.

[72]  M. Stiborová,et al.  Histone Deacetylase Inhibitors as Anticancer Drugs , 2017, International journal of molecular sciences.

[73]  F. Liu,et al.  Selective histone deacetylase small molecule inhibitors: recent progress and perspectives , 2017, Expert opinion on therapeutic patents.

[74]  Yanhua Du,et al.  Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression , 2017, Molecular medicine reports.

[75]  Y. Zou,et al.  Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells* , 2017, The Journal of Biological Chemistry.

[76]  S. Encarnación-Guevara,et al.  Lysine acetylation and cancer: A proteomics perspective. , 2017, Journal of proteomics.

[77]  A. Park,et al.  Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer , 2016, Yonsei medical journal.

[78]  Y. Peterson,et al.  Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia. , 2016, Journal of medicinal chemistry.

[79]  S. Mane,et al.  Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition , 2016, Proceedings of the National Academy of Sciences.

[80]  E. Seto,et al.  HDACs and HDAC Inhibitors in Cancer Development and Therapy. , 2016, Cold Spring Harbor perspectives in medicine.

[81]  Peter A. Jones,et al.  Targeting the cancer epigenome for therapy , 2016, Nature Reviews Genetics.

[82]  Kathleen R. Cho,et al.  New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. , 2016, Translational research : the journal of laboratory and clinical medicine.

[83]  D. F. Chedom,et al.  Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. , 2016, Cancer cell.

[84]  L. Jing,et al.  Down-regulation of SIRT3 promotes ovarian carcinoma metastasis. , 2016, Biochemical and biophysical research communications.

[85]  I. Shih,et al.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. , 2016, The American journal of pathology.

[86]  A. Wei,et al.  Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices. , 2016, Oncology reports.

[87]  Daoxiu Zhou,et al.  Histone Acetylation Enzymes Coordinate Metabolism and Gene Expression. , 2015, Trends in plant science.

[88]  Stephen T. C. Wong,et al.  Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. , 2015, American journal of physiology. Cell physiology.

[89]  Hang Lee,et al.  Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer , 2015, Cancer Chemotherapy and Pharmacology.

[90]  Malini Guha.  HDAC inhibitors still need a home run, despite recent approval , 2015, Nature Reviews Drug Discovery.

[91]  C. Ishioka,et al.  Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors , 2015, Cancer science.

[92]  Yuanlin Liu,et al.  Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms , 2014, Cancer Cell International.

[93]  M. Barnett,et al.  The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease , 2014, Nutrients.

[94]  Z. Xiong,et al.  Overexpression of MTA1 promotes invasiveness and metastasis of ovarian cancer cells , 2014, Irish Journal of Medical Science (1971 -).

[95]  G. Adema,et al.  HDAC inhibitors and immunotherapy; a double edged sword? , 2014, Oncotarget.

[96]  D. Marsh,et al.  Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets , 2014, Front. Oncol..

[97]  T. Tollefsbol,et al.  Pathway Modulations and Epigenetic Alterations in Ovarian Tumorbiogenesis , 2014, Journal of cellular physiology.

[98]  E. Seto,et al.  Erasers of histone acetylation: the histone deacetylase enzymes. , 2014, Cold Spring Harbor perspectives in biology.

[99]  M Choolani,et al.  An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530) , 2013, Cell Death and Disease.

[100]  D. Lombard,et al.  SIRT3: As Simple As It Seems? , 2013, Gerontology.

[101]  A. Sood,et al.  Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies , 2013, Investigational New Drugs.

[102]  M. Brewer,et al.  Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. , 2013, International journal of oncology.

[103]  O. Witt,et al.  HDAC11 is a novel drug target in carcinomas , 2013, International journal of cancer.

[104]  M. Rettenmaier,et al.  Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer , 2013, International Journal of Gynecologic Cancer.

[105]  Tongshan Wang,et al.  Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. , 2013, Future oncology.

[106]  Sungpil Yoon,et al.  Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. , 2012, Cancer letters.

[107]  R. Glasspool,et al.  Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer , 2012, International Journal of Gynecologic Cancer.

[108]  Joan L. Walker,et al.  A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[109]  Johan Auwerx,et al.  Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.

[110]  J. Prat.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features , 2012, Virchows Archiv.

[111]  Jinping Li,et al.  Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. , 2011, Future oncology.

[112]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[113]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[114]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[115]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[116]  B. Rueda,et al.  Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer , 2011, Journal of Ovarian Research.

[117]  Suzanne F. Jones,et al.  A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors. , 2011, Clinical advances in hematology & oncology : H&O.

[118]  J. Bartek,et al.  Correction: Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity , 2011, PLoS ONE.

[119]  Jiri Bartek,et al.  Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity , 2011, PloS one.

[120]  L. Cope,et al.  Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. , 2010, American journal of obstetrics and gynecology.

[121]  T. Shiozawa,et al.  Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin , 2010, International journal of cancer.

[122]  E. Lengyel.  Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[123]  J. Bono,et al.  A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours , 2010, British Journal of Cancer.

[124]  H. Mackay,et al.  Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. , 2010, European journal of cancer.

[125]  Jinping Li,et al.  Nonhistone protein acetylation as cancer therapy targets , 2010, Expert review of anticancer therapy.

[126]  D. Saur,et al.  E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. , 2009, Gastroenterology.

[127]  P. Kruk,et al.  Deacetylation of cortactin by SIRT1 promotes cell migration , 2009, Oncogene.

[128]  Kwun Chuen Gary Chan,et al.  Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor , 2008, Clinical Cancer Research.

[129]  Xiao-Fan Wang,et al.  The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. , 2008, Cancer research.

[130]  W. Weichert,et al.  Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. , 2008, Neoplasia.

[131]  E. Seto,et al.  Lysine acetylation: codified crosstalk with other posttranslational modifications. , 2008, Molecular cell.

[132]  S. Modesitt,et al.  A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[133]  E. Seto,et al.  The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men , 2008, Nature Reviews Molecular Cell Biology.

[134]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  S. Denslow,et al.  The human Mi-2/NuRD complex and gene regulation , 2007, Oncogene.

[136]  S. Murphy,et al.  Loss of betaglycan expression in ovarian cancer: role in motility and invasion. , 2007, Cancer research.

[137]  J. Mariadason,et al.  Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy , 2007, Cancer biology & therapy.

[138]  C. Pérez-Plasencia,et al.  A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors , 2007, BMC Cancer.

[139]  R. Agarwal,et al.  Mechanisms of transcoelomic metastasis in ovarian cancer. , 2006, The Lancet. Oncology.

[140]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[141]  L. Hongmei,et al.  Clinical Evaluation of E-cadherin Expression and its Regulation Mechanism in Epithelial Ovarian Cancer , 2006, Clinical & Experimental Metastasis.

[142]  H. Wanebo,et al.  Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. , 2006, International journal of oncology.

[143]  R. Ohlinger,et al.  Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients , 2006, BMC Cancer.

[144]  Xiang-Jiao Yang,et al.  Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication , 2005, Molecular and Cellular Biology.

[145]  Suk Woo Nam,et al.  Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[146]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[147]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[148]  G. Nicolson,et al.  Expression of the metastasis‐associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas , 2004, International journal of cancer.

[149]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[150]  Y. Mitani,et al.  Histone Acetylation and Gastrointestinal Carcinogenesis , 2003, Annals of the New York Academy of Sciences.

[151]  Kuang-Hung Cheng,et al.  Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code , 2003, Annals of the New York Academy of Sciences.

[152]  A. Bird,et al.  Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. , 1999, Genes & development.

[153]  L. Guarente,et al.  Extrachromosomal rDNA Circles— A Cause of Aging in Yeast , 1997, Cell.

[154]  F. Wang,et al.  Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. , 2019, Current topics in medicinal chemistry.

[155]  A. Kozikowski,et al.  Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors—What Some May Have Forgotten or Would Rather Forget? , 2016, ChemMedChem.

[156]  E. Obermayr,et al.  Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. , 2013, Gynecologic oncology.

[157]  Zhao Shan,et al.  Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[158]  陈亮.  Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis , 2010 .

[159]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[160]  Steven Grant,et al.  Vorinostat , 2007, Nature Reviews Drug Discovery.

[161]  Jung-Hyun Park,et al.  Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase , 2007, Journal of Molecular Medicine.

[162]  G. Nicolson,et al.  Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: Role in epithelial cancer cell invasion, proliferation and nuclear regulation , 2004, Clinical & Experimental Metastasis.